Scenesse
(Afamelanotide)ApprovedPeptide
Afamelanotide is used to help protect the skin of people with a rare condition called erythropoietic protoporphyria (EPP), which causes severe pain and burning when their skin is exposed to sunlight.[2] Scenesse is currently approved and in use across 3 indications[4].[1]
Scenesse is one of 64 small molecule programs targeting Cutaneous Porphyria. It is currently in Approved.
3
Indications
22
Total Trials
0
Active Trials
63
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Competition
Competitive Landscape
119 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Tnkase
RochePhase 3
Scenesse
CClinuvel, Inc.
Approved
Reminyl
WWim Janssens
Phase 3
Atorvastatin Calcium
Merck & Co.Phase 3
Butylphthalide
PPeking Union Medical College Hospital
Phase 3
PCSK9 Inhibitor
YYun Dai Chen
Phase 3
Zastaprazan
YYonsei University
Phase 3
Tenecteplase or Alteplase
IInsel Gruppe AG, University Hospital Bern
Phase 3
Proamatine
TakedaPreclinical
Levaquin
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Erythropoietic Protoporphyria6 trials
Vitiligo4 trials
Xeroderma Pigmentosum2 trials
Polymorphic Light Eruption2 trials
6 more indications
Variegate Porphyria1 trial
Stroke1 trial
Age1 trial
Regulatory
FDA Approval Timeline[5]
Oct 8, 2019
SCENESSE
NDA NDA210797
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Scenesse drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Afamelanotide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Melanocortin Receptor 1 Agonist[3]
- Modality
- Peptide[3]
- Highest Phase
- Approved[1]
- Company
- CClinuvel, Inc.
Patent Landscape[6]
Patent Cliff
Jan 20, 2033
Earliest patent expiration — generic entry possible after this date
Patent #Expires
8334265Jan 20, 2033